PK/PD Modeling

PK/PD (pharmacokinetic/pharmacodynamic) modeling quantitatively describes the relationship between drug exposure and biological response. By integrating pharmacokinetic data with pharmacodynamic endpoints—such as biomarkers, target engagement, efficacy, or safety—it helps researchers understand how changes in dose or exposure influence therapeutic outcomes. PK/PD modeling provides a scientific framework for optimizing dose selection, comparing drug candidates, and supporting evidence-based decision-making throughout drug discovery and preclinical development.

Pharmacokinetics (PK) describes how the body absorbs, distributes, metabolizes, and eliminates a drug over time, while pharmacodynamics (PD) describes the biological effects produced by the drug. PK answers "What does the body do to the drug?", whereas PD answers "What does the drug do to the body?" PK/PD modeling integrates these two disciplines to explain how drug exposure drives efficacy, biomarker responses, target engagement, or safety outcomes, providing a more complete understanding of drug action.

PK/PD modeling supports critical decision-making throughout drug discovery and preclinical development by evaluating exposure-response relationships and predicting therapeutic outcomes. It helps researchers compare drug candidates, optimize dose regimens, interpret efficacy and biomarker data, and improve the design of pharmacology and toxicology studies. These quantitative insights reduce development uncertainty and support more informed progression toward IND-enabling studies and clinical development.

PK/PD models simulate how different doses, dosing intervals, and treatment durations influence drug exposure and biological response. These simulations help identify dosing strategies that maximize efficacy while minimizing unnecessary drug exposure or safety risks. By evaluating multiple dosing scenarios before conducting additional studies, PK/PD modeling supports efficient study design and more informed dose selection throughout preclinical development.

PK/PD modeling can begin as soon as pharmacokinetic and pharmacodynamic data become available and should evolve throughout the drug development process. Early models support lead optimization and candidate selection, while more advanced models guide dose optimization, translational research, and first-in-human planning. As additional PK, efficacy, biomarker, and safety data are generated, the models can be refined to improve predictive performance and support regulatory decision-making.

Robust PK/PD models integrate multiple types of experimental data collected throughout drug discovery and preclinical development. These typically include dose information, concentration-time profiles, pharmacodynamic biomarkers, efficacy endpoints, and dosing schedules. Depending on the therapeutic mechanism, additional data such as target engagement, receptor occupancy, tissue exposure, disease progression, and safety observations may also be incorporated to improve model accuracy and predictive power.

PK/PD modeling is a core component of Model-Informed Drug Development (MIDD), a quantitative approach that integrates experimental data with mathematical models to improve development decisions. Within an MIDD framework, PK/PD models support candidate selection, dose optimization, translational research, study design, and first-in-human dose prediction. By reducing uncertainty and enabling data-driven decision-making, MIDD helps improve development efficiency and supports interactions with regulatory agencies.

Although all three approaches are used in quantitative drug development, they address different scientific questions. Physiologically based pharmacokinetic (PBPK) models predict drug disposition using physiological and anatomical parameters, while population PK models evaluate variability in pharmacokinetics across individuals or patient populations. PK/PD models focus on linking drug exposure to biological response, explaining how pharmacokinetic profiles influence efficacy, biomarkers, or safety. Together, these complementary modeling approaches provide a comprehensive foundation for model-informed drug development.

PK/PD modeling supports first-in-human dose selection by integrating preclinical pharmacokinetic, pharmacodynamic, and biomarker data with translational modeling approaches. Although dose selection also considers safety, toxicology, and regulatory requirements, PK/PD models help estimate exposure ranges associated with pharmacological activity and identify rational starting doses for clinical studies. When combined with PBPK modeling and allometric scaling, PK/PD modeling improves confidence in clinical dose predictions.